71.99
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$67.39
Aprire:
$67.83
Volume 24 ore:
5.09M
Relative Volume:
6.20
Capitalizzazione di mercato:
$2.30B
Reddito:
-
Utile/perdita netta:
$-38.99M
Rapporto P/E:
-24.02
EPS:
-2.9966
Flusso di cassa netto:
$-24.94M
1 W Prestazione:
+46.59%
1M Prestazione:
+60.01%
6M Prestazione:
+46.53%
1 anno Prestazione:
+68.20%
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Nome
Soleno Therapeutics Inc
Settore
Industria
Telefono
650-213-8444
Indirizzo
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Confronta SLNO con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
SLNO
Soleno Therapeutics Inc
|
71.99 | 2.30B | 0 | -38.99M | -24.94M | -2.9966 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-03-05 | Ripresa | Stifel | Buy |
2024-12-02 | Reiterato | Robert W. Baird | Outperform |
2024-12-02 | Reiterato | Stifel | Buy |
2024-09-03 | Iniziato | H.C. Wainwright | Buy |
2024-05-10 | Iniziato | Robert W. Baird | Outperform |
2024-02-05 | Iniziato | Piper Sandler | Overweight |
2024-01-23 | Iniziato | Stifel | Buy |
2023-11-21 | Ripresa | Guggenheim | Buy |
2020-09-29 | Iniziato | Guggenheim | Buy |
2020-01-10 | Iniziato | Craig Hallum | Buy |
2019-12-23 | Iniziato | Oppenheimer | Outperform |
2018-02-13 | Reiterato | Maxim Group | Buy |
Mostra tutto
Soleno Therapeutics Inc Borsa (SLNO) Ultime notizie
Soleno Therapeutics Stock (SLNO) Surges on FDA Green Light for PWS Treatment - Markets Insider
Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week? - Insider Monkey
10 Stocks Outperform Broader Market Last Week - Insider Monkey
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug - MSN
Why Soleno Therapeutics Inc. (SLNO) Went Up On Friday? - Yahoo Finance
Major Shareholder Sells Massive Stake in Soleno Therapeutics! - TipRanks
Vivo opportunity sells $124 million in Soleno Therapeutics stock - Investing.com
Guggenheim raises Soleno Therapeutics stock target to $81 By Investing.com - Investing.com South Africa
Stifel raises Soleno stock target to $108 after FDA approval By Investing.com - Investing.com South Africa
PANTHERx® Rare Selected by Soleno Therapeutics for the Distribution of VYKAT™ XR - PR Newswire
Stifel raises Soleno stock target to $108 after FDA approval - Investing.com
Soleno Therapeutics price target raised to $108 from $74 at Stifel - TipRanks
Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday? - Insider Monkey
Soleno Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily
FDA Greenlights Soleno Therapeutics’ VYKAT XR for PWS Hyperphagia - geneonline
Oppenheimer lifts Soleno Therapeutics stock target to $105 By Investing.com - Investing.com Canada
Soleno Therapeutics pulls in FDA nod for treatment for rare genetic disease - Mugglehead
Biotech Zooms Into Breakout Zone On Hard-Fought Approval - Investor's Business Daily
First Prader-Willi treatment Vykat XR FDA-approved: Soleno soars - BioWorld Online
Drugmaker Soleno Soars on Approval to Treat Never Ending Hunger - Bloomberg
Soleno Therapeutics: In No Rush To Join Buying Frenzy Despite Vykat Approval (SLNO) - Seeking Alpha
Soleno wins FDA approval for Prader-Willi hyperphagia treatment - Yahoo
Soleno Shares Are Up Today: What's Going On? - Benzinga
FDA Approves Soleno Therapeutics’ Vykat XR for Hyperphagia in Patients with Prader-Willi Syndrome - Pharmaceutical Executive
Baird Raises Soleno Therapeutics' Price Target to $102 From $72, Outperform Rating Maintained - Marketscreener.com
Soleno Therapeutics: A Breakthrough in Rare Disease Treatment - RagingBull
Soleno’s Vykat Gains First Prader-Willi Syndrome Approval, Rivals To Follow - Citeline News & Insights
Soleno stock skyrockets on FDA drug approval - Yahoo Finance
Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR - FiercePharma
Soleno jumps as analysts say US nod for rare disease drug transforms treatment options - MSN
Soleno Therapeutics execs reap stock windfall after FDA approves rare disease drugSan Francisco Business Times - The Business Journals
Piper Sandler maintains $93 target on Soleno Therapeutics stock By Investing.com - Investing.com South Africa
Soleno Skyrockets 40% on FDA Nod for VYKAT XR - Wall Street Pit
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday - Benzinga
Stifel maintains Soleno Therapeutics buy rating post FDA nod By Investing.com - Investing.com Australia
Behind the Scenes of Soleno Therapeutics's Latest Options Trends - Benzinga
SLNO stock touches 52-week high at $66.16 amid robust growth - Investing.com India
Stifel maintains Soleno Therapeutics buy rating post FDA nod - Investing.com India
Piper Sandler maintains $93 target on Soleno Therapeutics stock - Investing.com India
Cantor Fitzgerald lifts Soleno Therapeutics stock target to $123 By Investing.com - Investing.com Australia
Sector Update: Health Care - TradingView
Soleno Therapeutics Stock Rockets 34% Pre-Market After FDA Approves Prader-Willi Syndrome Drug: Retail Sentiment Peaks - MSN
Oppenheimer lifts Soleno Therapeutics stock target to $105 - Investing.com
Cantor Fitzgerald lifts Soleno Therapeutics stock target to $123 - Investing.com India
FDA approves Soleno’s Vykat XR as first treatment for hyperphagia in Prader-Willi syndrome - PMLiVE
Why Is Soleno Therapeutics Soaring On Thursday?Soleno Therapeutics (NASDAQ:SLNO) - Benzinga
Soleno stock price target raised to $102 by Baird - Investing.com India
Stifel maintains Soleno Therapeutics buy rating, $74 target - Investing.com India
Soleno shares surge on FDA approval of Vykat for Prader-Willi syndrome - Investing.com
Soleno shares surge on FDA approval of Vykat for Prader-Willi syndrome By Investing.com - Investing.com South Africa
Soleno gains as US FDA approves its drug to treat rare genetic disorder - TradingView
Soleno Therapeutics Inc Azioni (SLNO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):